Our Global Capital Confidence Barometer shows life sciences expectations continue to be positive, with 50% of executives planning to pursue M&A in the next year.
Life sciences M&A optimism resulted in record deal announcements first quarter
Choose your deal strategy wisely
2018 M&A Firepower Report: Life sciences deals and data
Life sciences deal intentions remain above trend
MDR and IVDR: reshaping Europe’s medtech industry
Looking beyond China to create a global IVD company
The operating room of the future
Medtech innovation for the aging world
Building value through creative deal structures
Finding sustainability in biotechnology, pharmaceutical and medical technology
Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.
Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.
We cover key issues in these areas:
More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world.
But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges.
We have been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry.
We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals.
So it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.
Take a closer look:
Pharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by this new world we call Pharma 3.0.
We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues, as well as our annual report on pharmaceutical industry trends, Progressions. Our thought leadership helps you navigate the shifting global landscape and grow your business — the new business imperative of improving health outcomes.
Today we stand on the cusp of the next big wave in improvements in health outcomes – driven not just by new products, but by behavioral change. We are moving to a world in which more emphasis will be on gathering evidence to identify interventions that are most effective at improving health outcomes, and then realigning the behavior of all stakeholders — patients, providers, manufacturers and others — around these interventions.
Take a closer look:
Nordic Industrial Products, Life Sciences Leader
+46 31 637811
Finnish Leader Life Sciences
+358 405 454 683
Connect with us
Stay connected with us through social media, email alerts or webcasts..
Robotic Process Automation
Ohjelmistorobotiikan avulla voit vähentää rutiininomaisista, manuaalisista töistä aiheutuvia kustannuksia jopa 70 % muuttamatta olemassa olevaa IT-infrastruktuuria. Samalla parannat asiakaskokemusta virheiden määrän laskiessa ja käsittelyaikojen pienentyessä. Lue lisää.
Nordic sales transformation in industrial products 2016
Gearing up for the race towards new digital reality
Download (pdf, 2mb)
Digitalization in industrial products
Technological innovation is rewriting every industry and the way in which human beings manage their lives. In this world, the ever increasing acceleration of change is one of the few constants.